Clinical Trials Logo

Vasospasm, Intracranial clinical trials

View clinical trials related to Vasospasm, Intracranial.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT02426827 Withdrawn - Cerebral Vasospasm Clinical Trials

Cervical Spinal Cord Stimulation in Cerebral Vasospasm

SCSinCV
Start date: July 2016
Phase: N/A
Study type: Interventional

The study is a non-blinded evaluation of the use of cervical spinal cord stimulation (SCS) for treatment of patients with Hunt and Hess grade 1-2 subarachnoid hemorrhage and evidence of cerebral vasospasm.

NCT ID: NCT02011321 Withdrawn - Clinical trials for Subarachnoid Hemorrhage

Clevidipine for Vasospasm After Subarachnoid Hemorrhage (SAH)

CLEVAS
Start date: March 2014
Phase: Phase 2
Study type: Interventional

Vasospasm occurs frequently after aneurysmal subarachnoid hemorrhage and can lead to strokes. The investigators will investigate if infusion of a novel drug, clevidipine, will decrease vasospasm during the infusion and post infusion period using transcranial doppler monitoring of patients with subarachnoid hemorrhage and moderate severity vasospasm

NCT ID: NCT01091870 Withdrawn - Clinical trials for Subarachnoid Hemorrhage

Sildenafil for Prevention of Cerebral Vasospasm

SIPCEVA
Start date: March 2010
Phase: Phase 2
Study type: Interventional

A Randomized Clinical Trial with security and dose testing of Sildenafil Citrate in patients with subarachnoid hemorrhage due to a rupture of a cerebral aneurism for prevention of cerebral vasospasm. The cerebral vasospasm is a decrease in blood flow that occurs when the intracranial vessels lose their capability of self-control of dilations and contractions. Patients with subarachnoid hemorrhage without neurological deficits who underwent endovascular or surgical correction of the aneurysm can participate in this trial. They will be randomized to a daily doses of 75 mg of Sildenafil, 150 mg of Sildenafil or Placebo from the third to the 14th day post bleeding. Today there is no proven clinical treatment for prevention of cerebral vasospasm.

NCT ID: NCT00871065 Withdrawn - Clinical trials for Subarachnoid Hemorrhage

Safety Study of Sildenafil in Treatment of Cerebral Aneurysm Vasospasm

Start date: July 2008
Phase: Phase 2
Study type: Interventional

Rupture of a cerebral aneurysm is a serious medical condition that may result in permanent disability or even death just related to the aneurysm rupture itself. Patients who undergo successful surgical treatment of their aneurysm will rarely experience problems related to that specific aneurysm in the future. However, blood that is on the surface of the brain from the initial aneurysm rupture is very irritating to other blood vessels that it comes in contact with. When these blood vessels become irritated, they spasm and become narrower. This narrowing restricts blood flow through the vessel, and if severe can result in a stroke that is caused by inadequate blood flow through the vessel. Depending on location and severity, this condition of vessel spasm (cerebral vasospasm) may result in permanent disability or death. Treatment to prevent cerebral vasospasm decreases the risk of stroke. This research is trying to see if a medication that is FDA approved for the treatment of lung disease and sexual dysfunction can be used to prevent and/or treat cerebral vasospasm.